Summary
Profile
Financials
Events
Ownership
Options

Company Info

Industry Biotechnology
Sector Health Technology
Employees 3,059
CEO Mr. Jean-Jacques Bienaimé
Address 770 Lindaro Street , San Rafael, CA 94901
Phone 1.415.506.6700
Website www.biomarin.com

BioMarin Pharmaceutical, Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its pipeline products include Valoctocogene roxaparvovec, Vosoritide, and BMN 307. The company was founded by John C. Klock, Christopher M. Starr and Grant W. Denison on March 21, 1997 and is headquartered in San Rafael, CA.

Competitors

Company Name 3 Month
%Change
1 Year
%Change
BioMarin Pharmaceutical, Inc. -3.97% 2.64%
Pfizer Inc. 13.16% 28.86%
Thermo Fisher Scientific, Inc. 23.12% 44.92%
Novo Nordisk A/S 25.05% 47.50%
Danaher Corp. 20.99% 58.14%

Statement Summary

as of 4:00 ET PM 09/23/2021
Total Assets (MRQ) 5.9 B
Total Liabilities (MRQ) 1.7 B
Shareholders’ Equity (MRQ) 4.2 B
Total Revenue (Annual) 504.4 M
Net Income (Annual) 12.9 M

Earnings And Estimates

as of 4:00 ET PM 09/23/2021

Current Qtr EPS Estimate -0.24
Current FY EPS Estimate -0.46
Long Term EPS Growth Estimate 51.10
Next Expected Earnings Date //

BMRN vs S&P 500

as of 09/23/2021
Relative To
S&P 500
BMRN
4 Weeks n/a n/a
12 Weeks n/a n/a
YTD n/a n/a

Earnings Surprises

as of 4:00 ET PM 09/23/2021
Fiscal Quarter Estimate Actual Surprise
06/2021 -0.11 0.07 -164.13%
03/2021 -0.09 0.09 -200.86%
12/2020 -0.17 0.12 -171.38%
09/2020 0.25 4.01 +1,504.00%
06/2020 -0.11 -0.16 +42.06%
03/2020 0.03 0.44 +1,316.93%
12/2019 -0.04 0.08 -319.18%
09/2019 0.06 0.30 +408.93%

Financial Strength

as of 4:00 ET PM 09/23/2021
Pre-Tax Margin 2.81
Net Margin 0.00
Operating Margin 3.86
Return On Equity 22.39
Return On Assets 14.95
Inventory Turnover (TTM) 0.86
Sales Growth (MRQ) 16.13

Ratios

as of 4:00 PM ET 09/23/2021
Price/Earnings (TTM) 18.72
Price/Book (MRQ) 3.43
Price/Cash Flow (TTM) 54.64
Book Value (MRQ) 23.14
Quick Ratio (MRQ) 3.71
Current Ratio (MRQ) 5.32
Total Debt/Equity (MRQ) 0.25

Short Interest

as of 4:00 PM ET 09/24/2021
% Short - 0.00%
% Remaining Float - 100.00%
Current Last Month
Short Interest Date n/a n/a
Short Interest Shares 0 0
Short Interest Ratio 0.0 0.0
M Y M Y
Total Assets 0,0.00 0,0.00
Total Liabilities 0,0.00 0,0.00
Total Equity 0,0.00 0,0.00
M Y M Y
Total Revenue 0,0.00 0,0.00
EBT Exc.
Unusual Items
0,0.00 0,0.00
Net Income 0,0.00 0,0.00
M Y M Y
Cash from
Operations
0,0.00 0,0.00
Cash from
Activities
0,0.00 0,0.00
Cash from
Fin. Activities
0,0.00 0,0.00

TOTAL ASSETS

TOTAL LIABILITIES

TOTAL EQUITY

Balance Sheet

M Y
ASSETS
Cash And Equivalents 0,0.00
Receivables 0,0.00
Inventories 0,0.00
Other Current Assets 0,0.00
Total Current Assets 0,0.00
Property, Plant & Equipment, Gross 0,0.00
Accumulated Depreciation & Depletion 0,0.00
Property, Plant & Equipment, Net 0,0.00
Intangibles 0,0.00
Other Non-Current Assets 0,0.00
Total Non-Current Assets 0,0.00
TOTAL ASSETS 0,0.00
Liabilities & Shareholder Equity
Accounts Payable 0,0.00
Short Term Debt 0,0.00
Total Current Liabilities 0,0.00
Long Term Debt 0,0.00
Deferred Income Taxes 0,0.00
Other Non-Current Liabilities 0,0.00
Minority Interest 0,0.00
Total Non-Current Liabilities 0,0.00
Preferred Stock Equity 0,0.00
Common Stock Equity 0,0.00
Common Par 0,0.00
Additional Paid In Capital 0,0.00
Cumulative Translation Adjustment 0,0.00
Retained Earnings 0,0.00
Treasury Stock 0,0.00
Other Equity Adjustments 0,0.00
Total Capitalization 0,0.00
TOTAL EQUITY 0,0.00
TOTAL LIABILITIES & STOCK EQUITY 0,0.00
Total Common Shares Outstanding 0,0.00
Preferred Shares 0,0.00
Treasury Shares 0,0.00
Basic Weighted Shares Outstanding 0,0.00
Diluted Weighted Shares Outstanding 0,0.00
Number Of Employees 0,0.00
Number Of Part-Time Employees 0,0.00

TOTAL REVENUES

EBT Excluding Unusual Items

NET INCOME

Income Statement

M Y
Sales 0,0.00
Cost Of Sales 0,0.00
Gross Operating Profit 0,0.00
Selling, General, And Administrative Expenses 0,0.00
Research & Development 0,0.00
Operating Income Before D & A (EBITDA) 0,0.00
Depreciation & Amortization 0,0.00
Interest Income 0,0.00
Other Income - Net 0,0.00
Special Income / Charges 0,0.00
Total Income Before Interest Expenses (EBIT) 0,0.00
Interest Expense 0,0.00
Pre-Tax Income 0,0.00
Income Taxes 0,0.00
Minority Interest 0,0.00
Net Income From Continuing Operations 0,0.00
Net Income From Discontinued Operations 0,0.00
Net Income From Total Operations 0,0.00
Extraordinary Income/Losses 0,0.00
Income From Cum. Effect Of Acct. Change 0,0.00
Income From Tax Loss Carryforward 0,0.00
Other Gains / Losses 0,0.00
Total Net Income 0,0.00
Normalized Income
(Net Income From Continuing Operations,
Ex. Special Income / Charge)
0,0.00
Preferred Dividends 0,0.00
Net Income Available To Common 0,0.00
Basic EPS From Continuing Ops. 0,0.00
Basic EPS From Discontinued Ops. 0,0.00
Basic EPS From Total Operations 0,0.00
Basic EPS From Extraordinary Inc. 0,0.00
Basic EPS From Cum Effect Of Accounting Change 0,0.00
Basic EPS From Tax Loss Carryf'd. 0,0.00
Basic EPS From Other Gains (Losses) 0,0.00
Basic EPS, Total 0,0.00
Basic Normalized Net Income/Share 0,0.00
EPS From Continuing Ops. 0,0.00
EPS From Discontinued Ops 0,0.00
EPS From Total Ops. 0,0.00
EPS From Extraord. Inc. 0,0.00
EPS From Cum Effect of Accounting Change 0,0.00
EPS From Tax Loss Carfd. 0,0.00
EPS From Other Gains (L) 0,0.00
EPS, Total 0,0.00
Diluted Normalized Net Inc/Shr
(Net Income From Continuing Operations,
Ex. Special Income / Charge)
0,0.00
Dividends Paid Per Share 0,0.00

CASH FROM OPERATIONS

CASH FROM INVESTING ACTIVITIES

CASH FROM FINANCING ACTIVITIES

Cash Flow Statement

M Y
Cash Flow From Operating Activities
Net Income (Loss) 0,0.00
Operating Gains/Losses 0,0.00
Gross Operating Profit 0,0.00
(Increase) Decrease In Receivables 0,0.00
(Increase) Decrease In Inventories 0,0.00
(Increase) Decrease In Other Current Assets 0,0.00
(Decrease) Increase In Other Current Liabilities 0,0.00
(Increase) Decrease In Other Working Capital 0,0.00
Other Non-Cash Items 0,0.00
Net Cash From Continuing Operations 0,0.00
Net Cash From Discontinued Operations 0,0.00
Cash Provided By Investing Activities
Net Cash From Total Operating Activities 0,0.00
Sale Of Property, Plant & Equipment 0,0.00
Cash Used For Investing Activities
Sale Of Short-Term Investments 0,0.00
Purchases Of Property, Plant & Equipment 0,0.00
Acquisitions 0,0.00
Purchases Of Short-Term Investments 0,0.00
Other Cash From Investing Activities 0,0.00
Cash Provided by Financing Activities
Net Cash From Investing Activities 0,0.00
Issuance Of Debt 0,0.00
Cash Used For Financing Activities
Issuance Of Capital Stock 0,0.00
Repayment Of Long-Term Debt 0,0.00
Repurchase Of Capital Stock 0,0.00
Payment Of Cash Dividends 0,0.00
Other Financing Charges, Net 0,0.00
Net Cash From Financing Activities 0,0.00
Effect Of Exchange Rate Changes 0,0.00
Net Change In Cash & Cash Equivalents 0,0.00

Earnings Estimates

as of 4:00 ET PM 09/23/2021
Current Qtr
(09/2021)
Next Qtr
(12/2021)
Consensus Estimate $-0.24 $-0.38
# of Estimates 16 15
High Estimate $-0.08 $-0.26
Low Estimate $-0.32 $-0.57
Year Ago EPS $4.33 $0.12
Year Over Year Growth Estimate -105.54% -413.34%
Current Yr
(12/2021)
Next Yr
(12/2022)
Consensus Estimate $-0.46 $0.79
# of Estimates 17 18
High Estimate $-0.33 $2.32
Low Estimate $-0.65 $-0.43
Year Ago EPS $4.41 $-0.46
Year Over Year Growth Estimate -110.52% -270.65%
Current Qtr
(09/2021)
Next Qtr
(12/2021)
Current Year
(12/2021)
Next Year
(12/2022)
Consensus Estimate $-0.24 $-0.38 $-0.46 $0.79
# of Estimates 16 15 17 18
High Estimate $-0.08 $-0.26 $-0.33 $2.32
Low Estimate $-0.32 $-0.57 $-0.65 $-0.43
Year Ago EPS $4.33 $0.12 $4.41 $-0.46
Year Over Year Growth Estimate -105.54% -413.34% -110.52% -270.65%

Insider Information Summary

as of 08/31/2021
% Insiders - 0.80%
% Remaining Total Shares - 99.20%
Current 1 Month
Net Insider Transaction -5.38 K 50.01 K
Shares Bought 1.00 K 129.82 K
Shares Sold 6.38 K 79.81 K

Insider Activity

Transaction Date Insider/Title Transaction Type Market Value Shares Average Price Current Holdings

LATEST NEWS

Recent Articles from TheStreet

Nikola

Tim Collins on How to Trade Nikola

Technical setups and short interest make much hated name volatile, and therefore interesting.

Chinese Firms Should Face Faster US Stock Delisting Over Audit Rules, SEC Chairman Gary Gensler Tells Lawmakers

Jim Cramer: Gensler's Plate is Very Full

SEC Chairman is key player in efforts to rein in ceaseless financial engineering.

stocks rise asset management sh

Cramer's Mad Money Recap: Advanced Micro Devices, Nvidia, Thor

Jim Cramer has your game plan for next week, which he says will be the calm before the earnings season storm.

Jim Cramer: Starbucks Needs More Traffic in Stores

Starbucks Resists Union Effort in New York Region: Report

Starbucks reportedly said it will raise wages and benefits and a union isn’t needed, to employees at three stores in Buffalo New York.

Exxon Mobil

Exxon, Occidental, Baker Hughes Make Goldman Turnaround List

Exxon has 'reduced costs, surprised to the downside on capital spending, outperformed our expectations in downstream/chemicals,' Goldman said.

videoblocks-a-series-of-fullhd-close-up-rotating-slider-dollymacro-shots-of-the-surface-of-computer-hardware-parts-chipsmotherboardcpucurcuits-close-up-macro-computer-chips-circuits-surface-rotating-dolly_s_mt0i43g_1080__D

Jim Cramer is Tired of the Weak Response to Chip Shortages

Companies need to forget about help from Washington and step up to the plate.

Microsoft Lead

Why 'Sarge' Guilfoyle Isn't Selling His Microsoft

Sharp management and strength across its business lines are keys to software giant.

Why Charles River Labs Is the Biotech Stock to Buy: Jim Cramer

Bret Jensen: Paratek Deal Shows Promise

While antibiotics are usually less profitable and slower to develop market share than other drugs, Paratek has a key factor in its favor.

Stocks Close Higher as Wall Street Dissects New Tax Laws

Stocks End Mixed Amid Evergrande Default Saga, Supply Chain Chaos

Evergrande's default saga, as well as mounting supply chain issues, have stocks trading mixed Friday.

bitcoin copy

Stock Market Today With Jim Cramer: China's Crypto Clampdown

Jim Cramer discusses China's crypto clampdown and Nike's report.